Correction: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer [Breast Cancer Res., 9, (2007) (R76)] DOI: 10.1186/bcr1789;Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Chang, Xin Zhong ^a,b   Li, Da Qiang ^a   Hou, Yi Feng ^a   Wu, Jiong ^a   Lu, Jin Song ^a   Di, Gen Hong ^a   Jin, Wei ^a   Ou, Zhou Luo ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PEROXIREDOXIN 6; RHOC PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; ETS1 PROTEIN, HUMAN; MICRORNA; PRDX6 PROTEIN, HUMAN; PRDX6 PROTEIN, MOUSE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN, HUMAN; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MDA MB 231HM CELL LINE; METASTASIS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PEROXIREDOXIN 6 GENE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CANCER INVASION; DISEASE COURSE; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PLASMID; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PEROXIREDOXIN VI; PLASMIDS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RNA INTERFERENCE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 40349106087     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-018-0984-0     Document Type: Erratum

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66.
2. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, et al: Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics. 2006, 6: 3352-3368 10.1002/pmic.200500617.
3. Shichi H, Demar JC: Non-selenium glutathione peroxidase without glutathione S-transferase activity from bovine ciliary body. Exp Eye Res. 1990, 50: 513-520 10.1016/0014-4835(90)90040-2.
4. Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H, et al: Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1 (supplement). DNA Res. 1995, 2: 51-59 10.1093/dnares/2.1.51.
5. Kim TS, Sundaresh CS, Feinstein SI, Dodia C, Skach WR, Jain MK, Nagase T, Seki N, Ishikawa K, Nomura N, et al: Identification of a human cDNA clone for lysosomal type Ca2+-independent phospholipase A2 and properties of the expressed protein. J Biol Chem. 1997, 272: 2542-2550 10.1074/jbc.272.4.2542.
6. Kang SW, Baines IC, Rhee SG: Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. J Biol Chem. 1998, 273: 6303-6311 10.1074/jbc.273.11.6303.
7. Manevich Y, Fisher AB: Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med. 2005, 38: 1422-1432 10.1016/j.freeradbiomed.2005.02.011.
8. Chang XZ, Wang ZM, Yu JM, Tian FG, Jin W, Zhang Y, Yu J, Li LF, Liu XF, Li ZW, et al: Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. Clin Exp Metastasis. 2007, 24: 25-38 10.1007/s10585-006-9053-7.
9. Zhang Z, Futamura M, Vikis HG, Wang M, Li J, Wang Y, Guan KL, You M: Positional cloning of the major quantitative trait locus underlying lung tumor susceptibility in mice. Proc Natl Acad Sci USA. 2003, 100: 12642-12647 10.1073/pnas.2133947100.
10. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47: 3239-3245.
11. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM: ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene. 2004, 23: 5799-5806 10.1038/sj.onc.1207765.
12. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001, 21: 2085-2090.
13. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003, 9: 3418-3424.
14. Liu Y, Liu H, Han B, Zhang JT: Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 2006, 66: 3248-3255 10.1158/0008-5472.CAN-05-3801.
15. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ: The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 2005, 65: 10338-10346 10.1158/0008-5472.CAN-04-4614.
16. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005, 23: 422-431 10.1200/JCO.2005.09.078.
17. Wang X, Phelan SA, Petros C, Taylor EF, Ledinski G, Jurgens G, Forsman-Semb K, Paigen B: Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis. Atherosclerosis. 2004, 177: 61-70 10.1016/j.atherosclerosis.2004.06.007.
18. Krapfenbauer K, Yoo BC, Fountoulakis M, Mitrova E, Lubec G: Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. Electrophoresis. 2002, 23: 2541-2547 10.1002/1522-2683(200208)23:15<2541::AID-ELPS2541>3.0.CO;2-1.
19. Krapfenbauer K, Engidawork E, Cairns N, Fountoulakis M, Lubec G: Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967: 152-160 10.1016/S0006-8993(02)04243-9.
20. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C: Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 2005, 65: 6773-6779 10.1158/0008-5472.CAN-05-1948.
21. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003, 424: 561-565 10.1038/nature01819.
22. de Souza GA, Godoy LM, Teixeira VR, Otake AH, Sabino A, Rosa JC, Dinarte AR, Pinheiro DG, Silva WA, Eberlin MN, et al: Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics. 2006, 6: 1460-1470 10.1002/pmic.200500243.
23. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006, 175: 1512-1516 10.1016/S0022-5347(05)00659-2.
24. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002, 196: 316-323 10.1002/path.1042.
25. Soini Y, Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang SW, Tammela TL, Peltoniemi M, Martikainen PM, Kinnula VL: Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. Apmis. 2006, 114: 329-337 10.1111/j.1600-0463.2006.apm_315.x.
26. Wiegand S, Dunne AA, Muller HH, Mandic R, Barth P, Davis RK, Werner JA: Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer. 2005, 104: 94-100 10.1002/cncr.21131.
27. Wang Y: The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev. 2001, 21: 146-170 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B.
28. Pillay V, Dass CR, Choong PF: The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 2007, 25: 33-39 10.1016/j.tibtech.2006.10.011.
29. Kim HJ, Park CI, Park BW, Lee HD, Jung WH: Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J. 2006, 47: 333-342.
30. Lincoln DW, Bove K: The transcription factor Ets-1 in breast cancer. Front Biosci. 2005, 10: 506-511 10.2741/1546.
31. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD: RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005, 93: 101-110 10.1007/s10549-005-4170-6.